NASDAQ:ACAD ACADIA Pharmaceuticals (ACAD) Stock Price, News & Analysis $26.00 -0.20 (-0.76%) Closing price 04:00 PM EasternExtended Trading$25.99 -0.01 (-0.04%) As of 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ACADIA Pharmaceuticals Stock (NASDAQ:ACAD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ACADIA Pharmaceuticals alerts:Sign Up Key Stats Today's Range$25.59▼$26.2950-Day Range$20.48▼$26.2052-Week Range$19.69▼$28.35Volume1.53 million shsAverage Volume1.67 million shsMarket Capitalization$4.45 billionP/E Ratio11.82Dividend YieldN/APrice Target$32.94Consensus RatingModerate Buy Company Overview ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics. The company’s flagship product, NUPLAZID® (pimavanserin), received U.S. Food and Drug Administration approval for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. Beyond NUPLAZID, ACADIA is pursuing additional indications for pimavanserin in dementia-related psychosis and Alzheimer’s disease psychosis, as well as exploring novel candidates for schizophrenia and other neuropsychiatric disorders. These efforts are complemented by strategic collaborations, translational research initiatives, and robust clinical trial programs to expand the company’s impact on patient care. ACADIA serves patients and healthcare providers primarily in North America, with ongoing clinical studies and regulatory submissions extending into Europe and Asia-Pacific regions. The company leverages partnerships with academic institutions and industry collaborators to accelerate development timelines and enhance its global footprint. Guided by a leadership team with extensive experience in CNS drug development, ACADIA continues to build on its scientific heritage and commitment to delivering differentiated therapies for complex neurological conditions.AI Generated. May Contain Errors. Read More ACADIA Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks92nd Percentile Overall ScoreACAD MarketRank™: ACADIA Pharmaceuticals scored higher than 92% of companies evaluated by MarketBeat, and ranked 28th out of 848 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingACADIA Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.65, and is based on no strong buy ratings, 12 buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialACADIA Pharmaceuticals has a consensus price target of $32.94, representing about 26.7% upside from its current price of $26.00.Amount of Analyst CoverageACADIA Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about ACADIA Pharmaceuticals' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth132.43% Earnings GrowthEarnings for ACADIA Pharmaceuticals are expected to grow by 132.43% in the coming year, from $0.37 to $0.86 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ACADIA Pharmaceuticals is 11.82, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 40.34.Price to Earnings Ratio vs. SectorThe P/E ratio of ACADIA Pharmaceuticals is 11.82, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.20.Price to Earnings Growth RatioACADIA Pharmaceuticals has a PEG Ratio of 18.87. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioACADIA Pharmaceuticals has a P/B Ratio of 3.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ACADIA Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.35% of the float of ACADIA Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 11.28, which indicates bearish sentiment.Change versus previous monthShort interest in ACADIA Pharmaceuticals has recently increased by 0.50%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldACADIA Pharmaceuticals does not currently pay a dividend.Dividend GrowthACADIA Pharmaceuticals does not have a long track record of dividend growth. News and Social Media4.4 / 5News Sentiment1.06 News SentimentACADIA Pharmaceuticals has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for ACADIA Pharmaceuticals this week, compared to 7 articles on an average week.Search Interest9 people have searched for ACAD on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.MarketBeat Follows3 people have added ACADIA Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ACADIA Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $219,813.00 in company stock.Percentage Held by Insiders26.20% of the stock of ACADIA Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.71% of the stock of ACADIA Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ACADIA Pharmaceuticals' insider trading history. Receive ACAD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACAD Stock News HeadlinesTardive Dyskinesia Market to Grow Rapidly at a CAGR of 8.1% During the Forecast Period (2026-2036) | DelveInsightJuly 8 at 3:31 PM | finance.yahoo.comACADIA Pharmaceuticals Inc.July 7 at 6:27 PM | edition.cnn.comTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.July 8 at 1:00 AM | Reagan Gold Group (Ad)Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People OfficerJuly 6 at 12:19 PM | finance.yahoo.comAcadia Pharmaceuticals Appoints Carl Segerstrom as Chief People OfficerJuly 6 at 9:04 AM | businesswire.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Average Recommendation of "Moderate Buy" from BrokeragesJuly 6 at 2:14 AM | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Elanco Animal Health (ELAN) and Bristol-Myers Squibb (BMY)June 30, 2026 | theglobeandmail.comStrength Seen in Acadia (ACAD): Can Its 6.8% Jump Turn into More Strength?June 29, 2026 | finance.yahoo.comSee More Headlines ACAD Stock Analysis - Frequently Asked Questions How have ACAD shares performed this year? ACADIA Pharmaceuticals' stock was trading at $26.71 at the beginning of the year. Since then, ACAD shares have decreased by 2.7% and is now trading at $26.00. How were ACADIA Pharmaceuticals' earnings last quarter? ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) posted its quarterly earnings results on Wednesday, May, 6th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.04 by $0.02. ACADIA Pharmaceuticals's revenue was up 9.7% compared to the same quarter last year. Read the conference call transcript. Who are ACADIA Pharmaceuticals' major shareholders? ACADIA Pharmaceuticals' top institutional shareholders include Assenagon Asset Management S.A. (0.01%) and GAMMA Investing LLC. Insiders that own company stock include Stephen Davis, Mark C Schneyer, Brendan Teehan, Austin D Kim, Elizabeth A Garofalo, James Kihara, Laura Brege, Jennifer J Rhodes and James M Daly. View institutional ownership trends. How do I buy shares of ACADIA Pharmaceuticals? Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ACADIA Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ACADIA Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings5/06/2026Today7/08/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2w+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 For the last 2 weeks, ACAD's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACAD CIK1070494 Webwww.acadia-pharm.com Phone(858) 558-2871Fax858-558-2872Employees510Year Founded1993Price Target and Rating Average Price Target for ACADIA Pharmaceuticals$32.94 High Price Target$40.00 Low Price Target$17.00 Potential Upside/Downside+26.7%Consensus RatingModerate Buy Rating Score (0-4)2.65 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)$2.20 Trailing P/E Ratio11.82 Forward P/E Ratio70.27 P/E Growth18.87Net Income$391 million Net Margins34.30% Pretax Margin10.51% Return on Equity9.61% Return on Assets7.07% Debt Debt-to-Equity RatioN/A Current Ratio3.59 Quick Ratio3.48 Sales & Book Value Annual Sales$1.07 billion Price / Sales4.16 Cash Flow$0.88 per share Price / Cash Flow29.53 Book Value$7.25 per share Price / Book3.59Miscellaneous Outstanding Shares171,240,000Free Float126,372,000Market Cap$4.45 billion OptionableOptionable Beta0.80 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:ACAD) was last updated on 7/8/2026 by MarketBeat.com Staff. From Our PartnersWe were the only ones who warned you …During the Great Financial Crisis, one firm accurately predicted 464 of 465 bank failures before they happened...Weiss Ratings | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredRay Dalio: Buy Gold. Get Paid.Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...Investors Alley | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredThese Wars Aren’t Really About What They Tell You…Nearly 20% of the global oil supply moves through the Strait of Hormuz - and rising tensions involving Iran ar...Cedar Gold Group | SponsoredFree: The Crypto Summit That Could Change Your LifeThe days when you could throw money at almost anything and watch it climb are gone. This is a market that rewa...Crypto 101 Media | SponsoredMake every rookie mistake for freeMost beginners think their first options trade has to be with real money. It doesn't. Every major broker has a...Profits Run | SponsoredIs your retirement account safe from new tax rulesWith Washington searching for new tax revenue, many retirement savers are taking a closer look at gold as a wa...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ACADIA Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACAD Stock Alerts